Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides

被引:230
作者
Fukushima, M [1 ]
Suzuki, N [1 ]
Emura, T [1 ]
Yano, S [1 ]
Kazuno, H [1 ]
Tada, Y [1 ]
Yamada, Y [1 ]
Asao, T [1 ]
机构
[1] Taisho Pharmaceut Co Ltd, Hanno Res Ctr, Hanno, Saitama 3578527, Japan
关键词
thymidine phosphorylase; uridine phosphorylase; competitive inhibitor; 5-trifluoromethyl-2 '-deoxyuridine; 5-iodo-2 '-deoxyuridine;
D O I
10.1016/S0006-2952(00)00253-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A new class of 5-halogenated pyrimidine analogs substituted at the 6-position was evaluated as competitive inhibitors of thymidine phosphorylase (TPase). The most potent member of the series was 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride (TPI), which has an apparent K-i value of 1.7 x 10(-8) M. TPI selectively inhibited the activity of TPase, but not that of uridine phosphorylase, thymidine kinase, orotate phosphoribosyltransferase, or dihydropyrimidine dehydrogenase. In vitro inhibition studies of TPI using a thymidine analogue, 5-trifluoromethyl-2'-deoxyuridine (F(3)dThd), as the substrate demonstrated that F(3)dThd phosphorolytic activity was inhibited markedly by TPI (1 x 10(-6) M) in extracts from the liver, small intestine, and tumors of humans, from the liver and small intestine of cynomolgus monkeys, and from the liver of rodents, but not from the liver or small intestine of dogs or the small intestine of rodents, suggesting that the distribution of TPase differs between humans and animal species, and that TPI could contribute to the modulation of TPase in humans. When F(3)dThd or 5-iodo-2'-deoxyuridine (IdUrd) was coadministered to mice with TPI at a molar ratio of 1:1, the blood levels of F(3)dThd (or IdUrd) were about 2-fold higher than when F(3)dThd (or IdUrd) was administered alone. In monkeys, the maximum concentration (C-max) and the area under the concentration-time curve (AUC) after oral F(3)dThd alone were 0.23 mu g/mL and 0.28 mu g . hr/mL, respectively, lour markedly increased to 15.18 mu g/mL (approximately 70-fold) and 28.47 mu g . hr/mL (approximately 100-fold), respectively, when combined with equimolar TPI. Combined oral administration of TPI significantly potentiated the antitumor activity of F(3)dThd on AZ-521 human stomach cancer xenografts in nude mice. In conclusion, TPI may contribute not only to inhibition of TPase-mediated biological functions but also to potentiation of the biological activity of various 2'-deoxyuridine and thymidine derivatives by combining with them. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:1227 / 1236
页数:10
相关论文
共 43 条
[1]  
ANSFIELD FJ, 1971, CANCER CHEMOTH REP 1, V55, P205
[2]  
BAKER BR, 1970, J MED CHEM, V13, P461, DOI 10.1021/jm00297a029
[3]   STUDIES OF FLUORINATED PYRIMIDINES .18. DEGRADATION OF 5-FLUORO-2'-DEOXY-URIDINE AND RELATED COMPOUNDS BY NUCLEOSIDE PHOSPHORYLASE [J].
BIRNIE, GD ;
KROEGER, H ;
HEIDELBERGER, C .
BIOCHEMISTRY, 1963, 2 (03) :566-&
[4]   CATABOLISM OF THYMIDINE IN HUMAN-BLOOD PLATELETS PURIFICATION AND PROPERTIES OF THYMIDINE PHOSPHORYLASE [J].
DESGRANGES, C ;
RAZAKA, G ;
RABAUD, M ;
BRICAUD, H .
BIOCHIMICA ET BIOPHYSICA ACTA, 1981, 654 (02) :211-218
[5]   PHOSPHOROLYSIS OF (E)-5-(2-BROMOVINYL)-2'-DEOXYURIDINE (BVDU) AND OTHER 5-SUBSTITUTED-2'-DEOXYURIDINES BY PURIFIED HUMAN THYMIDINE PHOSPHORYLASE AND INTACT BLOOD-PLATELETS [J].
DESGRANGES, C ;
RAZAKA, G ;
RABAUD, M ;
BRICAUD, H ;
BALZARINI, J ;
DECLERCQ, E .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (23) :3583-3590
[6]  
ELKOUNI MH, 1993, CANCER RES, V53, P3687
[7]   ANGIOGENIC FACTOR [J].
FURUKAWA, T ;
YOSHIMURA, A ;
SUMIZAWA, T ;
HARAGUCHI, M ;
AKIYAMA, S ;
FUKUI, K ;
ISHIZAWA, M ;
YAMADA, Y .
NATURE, 1992, 356 (6371) :668-668
[8]   INHIBITION OF URIDINE PHOSPHORYLASE BY SOME PYRIMIDINE-DERIVATIVES [J].
GRANCHAROV, K ;
MLADENOVA, J ;
GOLOVINSKY, E .
BIOCHEMICAL PHARMACOLOGY, 1991, 41 (11) :1769-1772
[9]  
IKENAKA K, 1981, GANN, V72, P590
[10]   IDENTIFICATION OF ANGIOGENIC ACTIVITY AND THE CLONING AND EXPRESSION OF PLATELET-DERIVED ENDOTHELIAL-CELL GROWTH-FACTOR [J].
ISHIKAWA, F ;
MIYAZONO, K ;
HELLMAN, U ;
DREXLER, H ;
WERNSTEDT, C ;
HAGIWARA, K ;
USUKI, K ;
TAKAKU, F ;
RISAU, W ;
HELDIN, CH .
NATURE, 1989, 338 (6216) :557-562